Saroglitazar Magnesium not checked
FollowEvery change as it happens, and a Monday email
Trials
5 active
17 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program”In the company’s words, NCT06427395 on ClinicalTrials.gov
- Tested for
- Primary Biliary Cholangitis (3 trials), Cholestatic Liver Disease (2 trials), Hepatic Impairment, Cirrhosis
- Main trialPhase 3
- “Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis”In the company’s words, NCT06427395 on ClinicalTrials.gov
- Other names
- Saroglitazar · Not any
Other drugs for Primary Biliary Cholangitis
- ElafibranorIpsen · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
- TH104Tharimmune Inc · Phase 2
- CilofexorGilead (Kite) · Phase 2
Coming up5
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 18 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- Nov 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 18 Apr 2027 | Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | |
| Phase 3Recruiting | Jul 2028 | Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy | |
| Phase 3Recruiting | Nov 2032 | Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes | |
| Phase 1Recruiting | 31 Dec 2026 | Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | |
| Phase 1Recruiting | 31 Dec 2026 | Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease | |
| Phase 4Unknown | 10 Jan 2025 | A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities | |
| Phase 2/3Completed | 30 Apr 2025 | Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis | |
| Phase 2Completed | 22 Aug 2019 | Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis | |
| Phase 2Completed | 20 Mar 2020 | Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis | |
| Phase 2Completed | 7 Aug 2020 | Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis | |
| Phase 2Completed | 13 Dec 2021 | Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) | |
| Phase 2Terminated | 2 Oct 2023 | Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US | |
| Phase 2Suspended | Dec 2023 | Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL | |
| Phase 2Terminated | 28 Oct 2024 | Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) | |
| Phase 2Completed | 12 Sep 2025 | Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis | |
| Phase 1Completed | 21 Mar 2022 | Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function | |
| Phase 1Completed | 28 May 2024 | A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026